Tim Ravenscroft, CEO of Lentigen, discusses a new partnership with IAVI on AIDS vaccine research and development at a Congressional Biomedical Research Caucus briefing in Washington DC on April 23. Read more.

Lentigen Awarded Phase II SBIR Grant for Clinical Development of TCR Immunotherapy Targeted to Melanoma [pdf]

Lentigen Awarded Phase I STTR Grant For Hunter Syndrome [pdf]

IAVI and Lentigen to Collaborate on Design of Novel AIDS Vaccine Candidate [pdf]

Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine [pdf]

Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement [pdf]

Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza [pdf]